The future of peptide compounding is at a critical crossroads. As the FDA prepares for its upcoming Pharmacy Compounding Advisory Committee (PCAC) meeting, compounders, prescribers, patients, and industry advocates are facing important decisions that could shape access to peptide therapies for years to come. In this episode, Amy Summers sits down with Melissa Stefko of Wells Pharmacy Network to discuss why these regulatory decisions matter. Together they explore the intersection of personalized medicine, patient access, regulatory oversight, and public safety.
Melissa Stefko is the senior VP of regulatory affairs at Wells Pharmacy Network with extensive experience in pharmacy compounding and FDA policy. She has been actively involved in peptide nominations for FDA review and works closely with industry organizations advocating for safe, regulated access to compounded therapies. Melissa brings a practical perspective on how evolving regulations impact pharmacies, physicians, and patients seeking personalized medicine.
Key Takeaways
- Why the upcoming FDA PCAC meeting could significantly impact peptide compounding.
- How peptide therapy fits into the growing movement toward personalized medicine.
- The safety concerns surrounding the expanding gray market for peptides.
- The difference between FDA enforcement discretion and state board pharmacy regulations.
- How pharmacists, physicians, and patients can contribute meaningful comments before FDA review.
Timestamps
[00:00] - Introduction to the episode
[04:07] - Why peptides have become a major healthcare and regulatory topic
[08:08] - Clinical uses for peptides and the original FDA nominations
[11:05] - FDA's preliminary recommendations and industry concerns
[15:16] - Gray market peptides versus regulated pharmacy compounding
[18:35] - Understanding FDA oversight and state board enforcement
[22:24] - How pharmacies, physicians, and patients can support the FDA review process
[26:08] - What meaningful FDA docket comments should include
[28:19] - Possible outcomes after the PCAC meeting
[33:10] - Final recommendations and how stakeholders can get involved
Follow Melissa Stefko:
- LinkedIn: https://www.linkedin.com/in/melissa-stefko-70234415/
- Website (Company): https://wellsrx.com/
- LinkedIn (Company): https://www.linkedin.com/company/wellspharmacynetwork/
- Facebook (Company): https://www.facebook.com/wellsrx
- Instagram (Company): https://www.instagram.com/wellspharmacynetwork/
- X (Company): https://x.com/wellsrx
- TikTok (Company): https://www.tiktok.com/@wellspharmacynetwork
Follow the Host:
- Amy Summers: https://www.linkedin.com/in/amy-summers-pharmd-bcscp-fapc-20b04a93/
- Restore Health Consulting: https://www.restorehealthconsulting.com/
Follow The Podcast:
- Spotify: https://open.spotify.com/show/033F4FRUbjSrN1oNbfozhD?si=caf30ccfd2ba49b6
- Apple Podcasts: https://podcasts.apple.com/in/podcast/compounding-interest/id6784679391
